vs
Absci Corp（ABSI）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是Absci Corp的1089.9倍（$708.5M vs $650.0K）。Medpace Holdings, Inc.净利率更高（19.1% vs -4548.0%，领先4567.1%）。Medpace Holdings, Inc.同比增速更快（32.0% vs -2.3%）。Medpace Holdings, Inc.自由现金流更多（$188.1M vs $-29.3M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -14.9%）
Absci Corp是一家结合合成生物学与人工智能技术的生物技术企业，为全球制药及生物制药合作伙伴提供集成式蛋白质工程解决方案，加速抗体、治疗性蛋白等新型生物候选药物的研发，助力满足未被覆盖的临床医疗需求。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
ABSI vs MEDP — 直观对比
营收规模更大
MEDP
是对方的1089.9倍
$650.0K
营收增速更快
MEDP
高出34.3%
-2.3%
净利率更高
MEDP
高出4567.1%
-4548.0%
自由现金流更多
MEDP
多$217.4M
$-29.3M
两年增速更快
MEDP
近两年复合增速
-14.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $650.0K | $708.5M |
| 净利润 | $-29.6M | $135.1M |
| 毛利率 | — | — |
| 营业利润率 | -4775.5% | 21.6% |
| 净利率 | -4548.0% | 19.1% |
| 营收同比 | -2.3% | 32.0% |
| 净利润同比 | -2.0% | 15.5% |
| 每股收益（稀释后） | $-0.19 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABSIMEDP
| Q4 25 | $650.0K | $708.5M | ||
| Q3 25 | $378.0K | $659.9M | ||
| Q2 25 | $593.0K | $603.3M | ||
| Q1 25 | $1.2M | $558.6M | ||
| Q4 24 | $665.0K | $536.6M | ||
| Q3 24 | $1.7M | $533.3M | ||
| Q2 24 | $1.3M | $528.1M | ||
| Q1 24 | $898.0K | $511.0M |
净利润ABSIMEDP
| Q4 25 | $-29.6M | $135.1M | ||
| Q3 25 | $-28.7M | $111.1M | ||
| Q2 25 | $-30.6M | $90.3M | ||
| Q1 25 | $-26.3M | $114.6M | ||
| Q4 24 | $-29.0M | $117.0M | ||
| Q3 24 | $-27.4M | $96.4M | ||
| Q2 24 | $-24.8M | $88.4M | ||
| Q1 24 | $-22.0M | $102.6M |
营业利润率ABSIMEDP
| Q4 25 | -4775.5% | 21.6% | ||
| Q3 25 | -7977.2% | 21.5% | ||
| Q2 25 | -5293.9% | 20.9% | ||
| Q1 25 | -2351.9% | 20.3% | ||
| Q4 24 | -4477.3% | 23.4% | ||
| Q3 24 | -1698.7% | 21.1% | ||
| Q2 24 | -2104.0% | 19.9% | ||
| Q1 24 | -2616.7% | 20.4% |
净利率ABSIMEDP
| Q4 25 | -4548.0% | 19.1% | ||
| Q3 25 | -7594.2% | 16.8% | ||
| Q2 25 | -5155.0% | 15.0% | ||
| Q1 25 | -2234.6% | 20.5% | ||
| Q4 24 | -4358.3% | 21.8% | ||
| Q3 24 | -1610.7% | 18.1% | ||
| Q2 24 | -1948.8% | 16.7% | ||
| Q1 24 | -2447.1% | 20.1% |
每股收益（稀释后）ABSIMEDP
| Q4 25 | $-0.19 | $4.65 | ||
| Q3 25 | $-0.20 | $3.86 | ||
| Q2 25 | $-0.24 | $3.10 | ||
| Q1 25 | $-0.21 | $3.67 | ||
| Q4 24 | $-0.26 | $3.67 | ||
| Q3 24 | $-0.24 | $3.01 | ||
| Q2 24 | $-0.22 | $2.75 | ||
| Q1 24 | $-0.22 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $497.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $189.4M | $459.1M |
| 总资产 | $216.3M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABSIMEDP
| Q4 25 | $144.3M | $497.0M | ||
| Q3 25 | $152.5M | $285.4M | ||
| Q2 25 | $38.0M | $46.3M | ||
| Q1 25 | $47.0M | $441.4M | ||
| Q4 24 | $112.4M | $669.4M | ||
| Q3 24 | $38.2M | $656.9M | ||
| Q2 24 | $42.9M | $510.9M | ||
| Q1 24 | $58.8M | $407.0M |
总债务ABSIMEDP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABSIMEDP
| Q4 25 | $189.4M | $459.1M | ||
| Q3 25 | $210.3M | $293.6M | ||
| Q2 25 | $173.4M | $172.4M | ||
| Q1 25 | $198.8M | $593.6M | ||
| Q4 24 | $179.1M | $825.5M | ||
| Q3 24 | $201.3M | $881.4M | ||
| Q2 24 | $221.5M | $763.6M | ||
| Q1 24 | $240.1M | $671.5M |
总资产ABSIMEDP
| Q4 25 | $216.3M | $2.0B | ||
| Q3 25 | $245.0M | $1.8B | ||
| Q2 25 | $209.9M | $1.6B | ||
| Q1 25 | $232.4M | $1.9B | ||
| Q4 24 | $213.6M | $2.1B | ||
| Q3 24 | $235.2M | $2.1B | ||
| Q2 24 | $255.5M | $1.9B | ||
| Q1 24 | $274.9M | $1.8B |
负债/权益比ABSIMEDP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-29.2M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $-29.3M | $188.1M |
| 自由现金流率自由现金流/营收 | -4505.4% | 26.6% |
| 资本支出强度资本支出/营收 | 15.8% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 1.43× |
| 过去12个月自由现金流最近4个季度 | $-94.2M | $681.9M |
8季度趋势，按日历期对齐
经营现金流ABSIMEDP
| Q4 25 | $-29.2M | $192.7M | ||
| Q3 25 | $-25.0M | $246.2M | ||
| Q2 25 | $-16.9M | $148.5M | ||
| Q1 25 | $-21.8M | $125.8M | ||
| Q4 24 | $-17.0M | $190.7M | ||
| Q3 24 | $-20.7M | $149.1M | ||
| Q2 24 | $-16.8M | $116.4M | ||
| Q1 24 | $-17.9M | $152.7M |
自由现金流ABSIMEDP
| Q4 25 | $-29.3M | $188.1M | ||
| Q3 25 | $-26.0M | $235.5M | ||
| Q2 25 | $-17.1M | $142.4M | ||
| Q1 25 | $-21.9M | $115.8M | ||
| Q4 24 | $-17.0M | $183.0M | ||
| Q3 24 | $-20.8M | $138.5M | ||
| Q2 24 | $-17.2M | $103.5M | ||
| Q1 24 | — | $147.2M |
自由现金流率ABSIMEDP
| Q4 25 | -4505.4% | 26.6% | ||
| Q3 25 | -6876.5% | 35.7% | ||
| Q2 25 | -2883.0% | 23.6% | ||
| Q1 25 | -1854.5% | 20.7% | ||
| Q4 24 | -2554.4% | 34.1% | ||
| Q3 24 | -1221.6% | 26.0% | ||
| Q2 24 | -1352.4% | 19.6% | ||
| Q1 24 | — | 28.8% |
资本支出强度ABSIMEDP
| Q4 25 | 15.8% | 0.6% | ||
| Q3 25 | 254.5% | 1.6% | ||
| Q2 25 | 37.6% | 1.0% | ||
| Q1 25 | 2.1% | 1.8% | ||
| Q4 24 | 3.5% | 1.4% | ||
| Q3 24 | 2.8% | 2.0% | ||
| Q2 24 | 26.2% | 2.4% | ||
| Q1 24 | 0.0% | 1.1% |
现金转化率ABSIMEDP
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABSI
暂无分部数据
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
